1. Home
  2. ACON vs CHEK Comparison

ACON vs CHEK Comparison

Compare ACON & CHEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACON
  • CHEK
  • Stock Information
  • Founded
  • ACON 2008
  • CHEK 2004
  • Country
  • ACON United States
  • CHEK Israel
  • Employees
  • ACON N/A
  • CHEK N/A
  • Industry
  • ACON Retail: Computer Software & Peripheral Equipment
  • CHEK Medical Electronics
  • Sector
  • ACON Technology
  • CHEK Health Care
  • Exchange
  • ACON Nasdaq
  • CHEK Nasdaq
  • Market Cap
  • ACON 4.1M
  • CHEK 4.3M
  • IPO Year
  • ACON 2022
  • CHEK 2015
  • Fundamental
  • Price
  • ACON $7.56
  • CHEK $0.76
  • Analyst Decision
  • ACON Buy
  • CHEK
  • Analyst Count
  • ACON 2
  • CHEK 0
  • Target Price
  • ACON $481.00
  • CHEK N/A
  • AVG Volume (30 Days)
  • ACON 17.6K
  • CHEK 29.6K
  • Earning Date
  • ACON 08-13-2025
  • CHEK 08-14-2025
  • Dividend Yield
  • ACON N/A
  • CHEK N/A
  • EPS Growth
  • ACON N/A
  • CHEK N/A
  • EPS
  • ACON N/A
  • CHEK N/A
  • Revenue
  • ACON $54,601.00
  • CHEK N/A
  • Revenue This Year
  • ACON $212.31
  • CHEK N/A
  • Revenue Next Year
  • ACON $92.86
  • CHEK N/A
  • P/E Ratio
  • ACON N/A
  • CHEK N/A
  • Revenue Growth
  • ACON N/A
  • CHEK N/A
  • 52 Week Low
  • ACON $6.20
  • CHEK $0.56
  • 52 Week High
  • ACON $3,499.51
  • CHEK $3.04
  • Technical
  • Relative Strength Index (RSI)
  • ACON 44.46
  • CHEK 45.42
  • Support Level
  • ACON $6.79
  • CHEK $0.75
  • Resistance Level
  • ACON $8.19
  • CHEK $0.86
  • Average True Range (ATR)
  • ACON 0.41
  • CHEK 0.03
  • MACD
  • ACON 0.29
  • CHEK 0.00
  • Stochastic Oscillator
  • ACON 45.69
  • CHEK 33.11

About ACON Aclarion Inc.

Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.

About CHEK Check-Cap Ltd.

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.

Share on Social Networks: